INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
NCT ID: NCT01367457
Last Updated: 2016-04-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
243 participants
OBSERVATIONAL
2011-01-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
NCT05891821
A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT00875667
CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma
NCT00033267
Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
NCT01389427
A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
NCT00413036
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients that received treatment with Temsirolimus
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Temsirolimus (Non-Interventional Study)
There is not any intervention in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Temsirolimus (Non-Interventional Study)
There is not any intervention in this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complexo Hospitalario Universitario A Coruña
A Coruña, A Coruña, Spain
Hospital de La Santa Creu I Sant Pau
Barcelona, Barcelona, Spain
Hospital Vall D'Hebron
Barcelona, Barcelona, Spain
Hospital del Mar
Barcelona, Barcelona, Spain
Hospital de Cabueñes
Cabueñes, Gijon, Spain
Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera
A Coruña, La Coruña, Spain
Hospital Clinico Universitario
Santiago de Compostela, La Coruña, Spain
Complejo Hospitalario Materno-Infantil Insular de Las Palmas
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital de Madrid Norte - Sanchinarro
Madrid, Madrid, Spain
Hospital de Navarra
Pamplona, Navarre, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Provincial de Castellon
Castellon, Valencia, Spain
Complejo AAsistencial de Avilla
Ávila, , Spain
MD Anderson Cancer Center
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INHIBITOR
Identifier Type: OTHER
Identifier Source: secondary_id
B1771017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.